Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma".

Autor: Bateman ED; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: eric.bateman@uct.ac.za., Khan AH; Sanofi, Chilly-Mazarin, France., Xu Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Guyot P; Sanofi, Chilly-Mazarin, France., Chao J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kamat S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Rowe P; Sanofi, Bridgewater, NJ, USA., Burnett H; Evidera, St-Laurent, Quebec, Canada., Msihid J; Sanofi, Chilly-Mazarin, France., Weinreich D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Pavord ID; Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2022 Jan; Vol. 191, pp. 106088. Date of Electronic Publication: 2020 Jul 09.
DOI: 10.1016/j.rmed.2020.106088
Databáze: MEDLINE
Externí odkaz: